|
Study of Karenitecin (BNP1350) in patients with brain tumors Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Study of Karenitecin (BNP1350) in patients with brain tumors conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Study of Karenitecin (BNP1350) in patients with brain tumors Clinical research trials and Study of Karenitecin (BNP1350) in patients with brain tumors health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Study of Karenitecin (BNP1350) in patients with brain tumors. Study of Karenitecin (BNP1350) in patients with brain tumors Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of Karenitecin (BNP1350) in patients with brain tumors clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Study of Karenitecin (BNP1350) in patients with brain tumors condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Karenitecin (BNP1350) in patients with brain tumors  Study of Karenitecin (BNP1350) in patients with brain tumors
Study of Karenitecin (BNP1350) in patients with brain tumors
For Condition: Brain Neoplasms,Brain Tumors,Malignant Neoplasms, Brain
Status: Recruiting
Sponsor(s): BioNumerik Pharmaceuticals, Inc. ,
Synopsis: The purpose of this study is to determine if Karenitecin (BNP1350) is effective in the treatment of Brain Tumors
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma. - Evidence of measurable recurrent or residual primary CNS neoplasm. - An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy. - Hematocrit > 29%, ANC > 1,500, platelets > 125,000 - Serum creatinine < 1.5 mg/dl, BUN < 25 mg/dl, serum SGOT and bilirubin < 1.5 times upper limit of normal - Negative pregnancy test for female patients
Total Enrollment:
Location and Contact Information:
For Information call 210-614-1701 for a site near you *Recruiting*
Durham, North Carolina, 27710
United States
Recruiting Clinical Department BioNumerik Pharmaceuticals 210-614-1701
Additional Information:
Study ID Numbers: KTN20405;
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00062478
Other Malignant Neoplasms, Brain Studies:
1. Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants with Brain Tumors
2. Study of Karenitecin (BNP1350) in patients with brain tumors
3. Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Related Studies:
Other Malignant Neoplasms, Brain Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
Study of Karenitecin (BNP1350) in patients with brain tumors
|
|
|
|
|
|
|
|
